| __timestamp | Mesoblast Limited | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 1860000 |
| Thursday, January 1, 2015 | 65378000 | 2963000 |
| Friday, January 1, 2016 | 52263000 | 6961000 |
| Sunday, January 1, 2017 | 35072000 | 11779000 |
| Monday, January 1, 2018 | 27415000 | 13697000 |
| Tuesday, January 1, 2019 | 36983000 | 15749000 |
| Wednesday, January 1, 2020 | 50918000 | 18638000 |
| Friday, January 1, 2021 | 63586000 | 27196000 |
| Saturday, January 1, 2022 | 57967000 | 31739000 |
| Sunday, January 1, 2023 | 53107000 | 33491000 |
| Monday, January 1, 2024 | 23626000 |
Cracking the code
In the competitive world of biotechnology, effective cost management is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and Mesoblast Limited from 2014 to 2023. Over this period, Mesoblast Limited's SG&A expenses fluctuated, peaking in 2015 and 2021, with a notable 64% increase from 2018 to 2021. Meanwhile, Protagonist Therapeutics, Inc. exhibited a steady upward trend, with expenses rising nearly 18-fold from 2014 to 2023. This growth reflects the company's expansion and increased operational activities. However, the data for 2024 is incomplete, highlighting the need for ongoing monitoring. Understanding these trends provides valuable insights into each company's strategic priorities and financial health, offering a window into their operational efficiency and market positioning.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Mesoblast Limited
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Mesoblast Limited
SG&A Efficiency Analysis: Comparing argenx SE and Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Mesoblast Limited vs Evotec SE: SG&A Expense Trends